In Q4FY15, total revenues of Alembic Pharmaceuticals increased by 8.4% YoY to Rs5.03 bn (our estimates Rs5.06 bn) compared to Rs4.64 bn in Q4FY14, due to higher domestic formulations sales. The Company's operating margins were at similar levels at 19.7% on back of higher other expenses which offset higher gross margins.